Key result
Low-dose aliskiren and low-dose losartan effectively reduced mortality and target-organ damage with minimal effects on blood pressure in a double-transgenic rat model.
Why the study?
Does low-dose aliskiren or losartan reduce mortality and target-organ damage in a double-transgenic rat model of hypertension?
Does low-dose aliskiren or losartan reduce mortality and target-organ damage in a double-transgenic rat model of hypertension?
Answers are grounded in this paper and cite their sources.
Low-dose RAS inhibition with aliskiren or losartan reduces mortality and target-organ damage independently of significant blood pressure lowering in a transgenic rat model of hypertension.
We studied the effects of extremely low-dose human renin inhibition (aliskiren) with low angiotensin II receptor blockade (losartan) in a novel double-transgenic rat model harbouring both human renin and angiotensinogen genes. We found that low-dose aliskiren and low-dose losartan effectively reduced mortality and target-organ damage with minimal, non-significant, effects on blood pressure (BP). Our data suggest that renin-angiotensin system (RAS) inhibition ameliorates target-organ damage in an Ang II-driven model of hypertension. Direct renin inhibition is equally efficacious in this regard. Our study does not fully answer the question of BP-lowering versus RAS inhibition. This question is important and was at least partially addressed with our low-dose model.
No takes yet. Share an insight, caveat, or question.
Dechend et al. (2007) studied Hypertension (Ang II-driven model). Aliskiren and losartan was evaluated on Mortality and target-organ damage. Low-dose aliskiren and low-dose losartan effectively reduced mortality and target-organ damage with minimal effects on blood pressure in a double-transgenic rat model.
Synapse has enriched 10 related papers. Consider them for comparative context: